Journal Mobile Options
Table of Contents
Vol. 21, No. 3, 2006
Issue release date: February 2006
Dement Geriatr Cogn Disord 2006;21:139–143

The Brain-Derived Neurotrophic Factor Gene as a Possible Susceptibility Candidate for Alzheimer’s Disease in a Chinese Population

Tsai S.-J. · Hong C.-J. · Liu H.-C. · Liu T.-Y. · Liou Y.-J.
Departments of aPsychiatry and bMedical Research and Education, cNeurological Institute, Taipei Veterans General Hospital, dSchool of Medicine, eInstitute of Clinical Medicine, National Yang-Ming University, Taipei, fDepartment of Psychiatry, Yuli Veterans Hospital, Hualien, Taiwan, ROC

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Brain-derived neurotrophic factor (BDNF), a member of the neurotrophic factor family, may represent a candidate gene conferring susceptibility to Alzheimer’s disease (AD). This is because it has an important role in neuronal survival, and a decreased central level of BDNF is observed in AD. Some previous studies, though not all, have demonstrated that BDNF C270T polymorphisms might be associated with AD susceptibility. We examined the association of the C270T polymorphisms with sporadic AD in a Chinese cohort of 175 AD patients and 189 controls. We also tested BDNF Val66Met-C270T haplotypes for an interaction with the apolipoprotein E υ4 (APOE4) allele in AD. The results showed that the frequency of the 66Val allele was significantly lower in AD than controls (p = 0.031), but no significant difference in C270T allele or genotype frequencies was observed between AD cases and controls. Global case-control haplotype analysis showed that there is significant difference in haplotype distribution between both groups (p = 0.033). Stratification of the data according to the APOE status showed that in APOE4 allele bearers there was no significant difference in the frequency of haplotype 66Val-270C between AD and controls (p = 0.125), although there was a significant difference between the two groups in non-APOE4 carriers (p = 0.002). These results suggest that BDNF genetic variation may possibly affect the risk for AD, particularly in subjects who are negative for APOE4.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Hofer M, Pagliusi SR, Hohn A, Leibrock J, Barde YA: Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. EMBO J 1990;9:2459–2464.
  2. Mufson EJ, Kroin JS, Sendera TJ, Sobreviela T: Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog Neurobiol 1999;57:451–484.
  3. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW: BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease. Neuron 1991;7:695–702.
  4. Murray KD, Gall CM, Jones EG, Isackson PJ: Differential regulation of brain-derived neurotrophic factor and type II calcium/calmodulin-dependent protein kinase messenger RNA expression in Alzheimer’s disease. Neuroscience 1994;60:37–48.
  5. Narisawa-Saito M, Wakabayashi K, Tsuji S, Takahashi H, Nawa H: Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer’s disease. Neuroreport 1996;7:2925–2928.
  6. Connor B, Young D, Yan Q, Faull RL, Synek B, Dragunow M: Brain-derived neurotrophic factor is reduced in Alzheimer’s disease. Brain Res Mol Brain Res 1997;49:71–81.
  7. Hock C, Heese K, Hulette C, Rosenberg C, Otten U: Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol 2000;57:846–851.
  8. Michalski B, Fahnestock M: Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer’s disease. Brain Res Mol Brain Res 2003;111:148–154.
  9. Murer MG, Boissiere F, Yan Q, Hunot S, Villares J, Faucheux B, Agid Y, Hirsch E, Raisman-Vozari R: An immunohistochemical study of the distribution of brain-derived neurotrophic factor in the adult human brain, with particular reference to Alzheimer’s disease. Neuroscience 1999;88:1015–1032.
  10. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR: The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003;112:257–269.
  11. Ventriglia M, Bocchio Chiavetto L, Benussi L, Binetti G, Zanetti O, Riva MA, Gennarelli M: Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer’s disease. Mol Psychiatry 2002;7:136–137.
  12. Tsai SJ, Hong CJ, Liu HC, Liu TY, Hsu LE, Lin CH: Association analysis of brain-derived neurotrophic factor Val66Met polymorphisms with Alzheimer’s disease and age of onset. Neuropsychobiology 2004;49:10–12.
  13. Combarros O, Infante J, Llorca J, Berciano J: Polymorphism at codon 66 of the brain-derived neurotrophic factor gene is not associated with sporadic Alzheimer’s disease. Dement Geriatr Cogn Disord 2004;18:55–58.
  14. Nacmias B, Piccini C, Bagnoli S, Tedde A, Cellini E, Bracco L, Sorbi S: Brain-derived neurotrophic factor, apolipoprotein E genetic variants and cognitive performance in Alzheimer’s disease. Neurosci Lett 2004;367:379–383.
  15. Bagnoli S, Nacmias B, Tedde A, Guarnieri BM, Cellini E, Petruzzi C, Bartoli A, Ortenzi L, Sorbi S: Brain-derived neurotrophic factor genetic variants are not susceptibility factors to Alzheimer’s disease in Italy. Ann Neurol 2004;55:447–448.
  16. Desai P, Nebes R, DeKosky ST, Kamboh MI: Investigation of the effect of brain-derived neurotrophic factor (BDNF) polymorphisms on the risk of late-onset Alzheimer’s disease (AD) and quantitative measures of AD progression. Neurosci Lett 2005;379:229–234.
  17. Bodner SM, Berrettini W, van Deerlin V, Bennett DA, Wilson RS, Trojanowski JQ, Arnold SE: Genetic variation in the brain derived neurotrophic factor gene in Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet 2005;134:1–5.
  18. Matsushita S, Arai H, Matsui T, Yuzuriha T, Urakami K, Masaki T, Higuchi S: Brain-derived neurotrophic factor gene polymorphisms and Alzheimer’s disease. J Neural Transm 2005;112:703–711.
  19. Nishimura M, Kuno S, Kaji R, Kawakami H: Brain-derived neurotrophic factor gene polymorphisms in Japanese patients with sporadic Alzheimer’s disease, Parkinson’s disease, and multiple system atrophy. Mov Disord 2005; 20:1031–1033.
  20. Vepsalainen S, Castren E, Helisalmi S, Iivonen S, Mannermaa A, Lehtovirta M, Hanninen T, Soininen H, Hiltunen M: Genetic analysis of BDNF and TrkB gene polymorphisms in Alzheimer’s disease. J Neurol 2005;252:423–428.
  21. Kunugi H, Ueki A, Otsuka M, Isse K, Hirasawa H, Kato N, Nabika T, Kobayashi S, Nanko S: A novel polymorphism of the brain-derived neurotrophic factor (BDNF) gene associated with late-onset Alzheimer’s disease. Mol Psychiatry 2001;6:83–86.
  22. Riemenschneider M, Schwarz S, Wagenpfeil S, Diehl J, Muller U, Forstl H, Kurz A: A polymorphism of the brain-derived neurotrophic factor (BDNF) is associated with Alzheimer’s disease in patients lacking the apolipoprotein E epsilon4 allele. Mol Psychiatry 2002;7:782–785.
  23. Oliveira JR, Mitne-Neto M, Guindalini C, Nitrini R, Bahia VS, de Brito-Marques PR, Otto PA, Zatz M: Lack of association between the brain-derived neurotrophin factor (C-270T) polymorphism and late-onset Alzheimer’s disease (LOAD) in Brazilian patients. J Mol Neurosci 2004;22:257–260.
  24. Liu HC, Hong CJ, Liu TY, Chi CW, Tsai SJ: Association analysis for the muscarinic M1 receptor genetic polymorphisms and Alzheimer’s disease. Dement Geriatr Cogn Disord 2005;19:42–45.
  25. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  26. Wenham PR, Price WH, Blandell G: Apolipoprotein E genotyping by one-stage PCR. Lancet 1991;337:1158–1159.
  27. Zhao JH, Lissarrague S, Essioux L, Sham PC: GENECOUNTING: haplotype analysis with missing genotypes. Bioinformatics 2002;18:1694–1695.
  28. Zhao JH, Curtis D, Sham PC: Model-free analysis and permutation tests for allelic associations. Hum Hered 2000;50:133–139.
  29. Zhao JH, Sham PC: Faster haplotype frequency estimation using unrelated subjects. Hum Hered 2002;53:36–41.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50